Fexofenadine in Pregnancy
Fexofenadine can be used during pregnancy when clinically indicated, as animal studies show no teratogenicity and emerging human data demonstrate no increased risk of major birth defects or adverse fetal outcomes.
Evidence Summary
FDA Classification and Animal Data
Fexofenadine is classified as FDA Pregnancy Category C 1. Animal studies in rats and rabbits at doses up to 300 mg/kg (approximately 3-30 times human exposure) showed no evidence of teratogenicity 1. However, the Category C designation reflects the absence of adequate controlled studies in pregnant women, not evidence of harm.
Human Safety Data
Recent high-quality evidence supports fetal safety:
A 2020 Danish nationwide registry study of 1,287,668 pregnancies found no increased risk when comparing fexofenadine to cetirizine use 2:
- Major birth defects: 4.0% vs 3.8% (OR 1.06,95% CI 0.81-1.37)
- Spontaneous abortion: 8.4% vs 9.0% (HR 0.93,95% CI 0.82-1.07)
- Preterm birth: 7.5% vs 7.7% (OR 0.97,95% CI 0.83-1.12)
- No increased risk of stillbirth or small for gestational age
A 2026 Japanese cohort study found major birth defects in only 1.8% of fexofenadine-exposed pregnancies (n=231), identical to the 1.8% control rate, with no consistent pattern of anomalies 3
Guideline Recommendations
Multiple 2008 guidelines from the Journal of Allergy and Clinical Immunology consistently state: "Although there are no reports of increased congenital malformations with the use of fexofenadine during pregnancy and animal studies are negative for teratogenicity, no epidemiologic studies in human pregnancy have been published" at that time 4. This caveat is now outdated given the 2020 and 2026 human studies.
The guidelines note that second-generation antihistamines as a class have excellent safety records with no significant increase in congenital malformations when used during the first trimester 4.
Clinical Approach
When to Use Fexofenadine
Fexofenadine is appropriate when:
- Allergic rhinitis or urticaria symptoms require systemic antihistamine therapy
- First-line options (intranasal corticosteroids, sodium cromolyn) are insufficient 4
- The patient has previously responded well to fexofenadine
- Non-sedating antihistamine properties are preferred over first-generation agents
Preferred Alternatives
While fexofenadine appears safe, consider these options with more extensive pregnancy data:
- Cetirizine or loratadine - More robust human pregnancy data from large registries 5, 6, 2
- Chlorpheniramine (first-generation) - Longest safety track record, though sedating 4
- Intranasal corticosteroids - Preferred for allergic rhinitis when topical therapy suffices 4
Important Caveats
Avoid these antihistamines:
- Hydroxyzine - Specifically contraindicated in early pregnancy based on animal data 4, 5, 4
- Diphenhydramine - Case-control study suggests possible cleft palate association 4
Administration considerations:
- Take fexofenadine with water, not fruit juices (grapefruit, orange, apple reduce bioavailability by 36%) 1
- Avoid concurrent aluminum/magnesium antacids (reduce absorption by 41%) 1
Risk-Benefit Discussion
The critical principle: The first trimester (organogenesis period) is most critical for teratogenic concerns 4. However, untreated severe allergic disease poses maternal risks that may outweigh theoretical fetal concerns 7.
Key counseling points:
- No human evidence of increased birth defects with fexofenadine
- Animal studies at high doses show no teratogenicity
- Recent large-scale human studies (>3,000 exposures) demonstrate safety
- Benefits of symptom control must be weighed against theoretical risks
The 2020 ERS/TSANZ guidelines emphasize that maternal disease control is paramount, as severe uncontrolled symptoms pose documented risks to both mother and fetus 7.
Bottom Line
Fexofenadine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (FDA language) 1. However, emerging evidence from 2020-2026 strongly suggests this risk is minimal to absent. When systemic antihistamine therapy is needed, fexofenadine represents a reasonable choice, particularly if the patient has responded well previously. Consider cetirizine or loratadine as alternatives with slightly more extensive human pregnancy data if starting new therapy.